Experience Using Efgartigimod to Treat Juvenile Myasthenia Gravis in China: A Multicenter Retrospective Study - PubMed
4 days ago
- #Pediatric Neurology
- #Efgartigimod
- #Juvenile Myasthenia Gravis
- Efgartigimod was studied for treating Juvenile Myasthenia Gravis (JMG) in a Chinese pediatric population.
- The study was a multicenter retrospective analysis involving 17 JMG patients under 18 years.
- Patients showed significant improvement in MG-ADL and QMG scores post-treatment with efgartigimod.
- 70.6% to 91.7% of patients achieved clinically meaningful improvement from week 1 to week 4.
- No treatment-related adverse events were reported, indicating a favorable safety profile.
- The study highlights the need for more pediatric-specific clinical evidence in JMG treatment.